Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. Schedule 13G/A (Amendment No. 2) reports that Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen each report 0% beneficial ownership of Relay Therapeutics common stock as of the close of business on March 31, 2026. The filing lists the reporting persons' principal business address in Stamford, Connecticut and identifies the class by CUSIP 75943R102.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in an open-market transaction at a weighted average price of $12.86 per share. The trade was carried out under a Rule 10b5-1 trading plan adopted on October 30, 2025.
After this sale, he directly holds 195,178 shares, which include 9,807 shares underlying restricted stock units. The transaction was executed in multiple trades at prices ranging from $12.67 to $13.42 per share.
Relay Therapeutics, Inc. officer Thomas Catinazzo reported a proposed sale of 37,234 common shares, with an aggregate market value of $492,233.48 and an approximate sale date of May 14, 2026. Morgan Stanley Smith Barney LLC is named as the broker.
The shares were acquired when restricted and performance stock units vested during January 27, January 29 and April 29, 2025. The notice gives October 30, 2025 as the Rule 10b5-1 plan adoption date. It also lists four sales by Thomas J. Catinazzo during the prior three months: 972 shares on April 28 for gross proceeds of $14,375.88; 1,800 shares on April 9 for $27,000.00; 17,717 shares on April 7 for $230,577.90; and 17,717 shares on March 9 for $178,280.86.
Relay Therapeutics reported first quarter 2026 results and highlighted major clinical progress for its lead PI3Kα inhibitor zovegalisib.
Revenue was $3.0 million for Q1 2026 versus $7.7 million a year earlier, while R&D expenses were $70.6 million and G&A expenses $11.0 million. Net loss narrowed to $73.3 million, or $0.41 per share, compared with a net loss of $77.1 million, or $0.46 per share, in Q1 2025.
Cash, cash equivalents and investments rose to $642.1 million as of March 31, 2026, helped by $137.1 million in at-the-market equity proceeds, and are expected to fund operations into 2029. Strategically, zovegalisib received FDA Breakthrough Therapy designation in advanced HR+/HER2- breast cancer, showed 11.1‑month median progression-free survival in a Phase 1/2 trial, and delivered a 44% objective response rate in a triplet regimen in heavily pre-treated patients. The company also initiated a Phase 1/2 trial for RLY‑8161, an NRAS-selective inhibitor, and plans a Phase 3 frontline breast cancer study in early 2027.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo had 972 shares of common stock sold on April 28, 2026 at $14.79 per share. According to the disclosure, this transaction was executed to cover his income tax withholding obligations from the vesting of 3,268 restricted stock units on April 27, 2026 and he had no discretion over the sale, which followed company policies.
After this tax-related sale, Catinazzo beneficially owned 212,895 shares of Relay Therapeutics common stock, including 9,807 shares underlying restricted stock units.
Relay Therapeutics, Inc. executive Peter Rahmer reported an open-market sale of 753 shares of common stock at $14.79 per share. According to the footnotes, the sale was made solely to cover income tax withholding on the vesting of 3,051 restricted stock units and was not discretionary. After this transaction, Rahmer directly owns 275,857 shares of Relay Therapeutics common stock, including 9,153 shares underlying RSUs, indicating the sale was small relative to his overall position.
Relay Therapeutics, Inc. President of R&D Donald A. Bergstrom reported a small, tax-related share sale. On April 28, 2026, he sold 1,490 shares of common stock at $14.79 per share. A footnote explains the sale covered income tax withholding on 5,012 RSUs that vested on April 27, 2026 and that he had no discretion over the transaction, which followed company policies for RSU vesting. After this sale, he directly holds 418,557 shares, including 15,037 shares underlying RSUs.
Relay Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Key items include electing two Class III directors, an advisory approval of named executive officer pay, and ratifying Ernst & Young LLP as independent auditor for 2026.
The board is also seeking approval to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders of record as of April 13, 2026 may vote online, by phone, by mail, or during the webcast. The board recommends voting "FOR" all four proposals.